摘要:目的:观察加味益气丸联合养血止痛丸治疗骶髂关节致密性骨炎的临床疗效及安全性。方法:将54例骶髂关节致密性骨炎患者随机分为治疗组和对照组,每组27例。治疗组口服加味益气丸和养血止痛丸,每次各6 g,每日2次;对照组口服塞来昔布胶囊,每次200 mg,每日2次。两组均以4周为1个疗程。观察两组治疗前和治疗3,7,14,28 d 及治疗结束2周后 NRS 评分改善情况及临床疗效,并对不良反应进行评价。结果:治疗组治愈7例,显效13例,好转5例,无效2例,总有效率为92.59%;对照组治愈2例,显效5例,好转11例,无效8例,总有效率为69.23%。两组比较,差异有统计学意义(P <0.05)。治疗后,两组各时间点 NRS 评分较治疗前均有下降,差异有统计学意义(P <0.05)。组间比较,治疗3,7 d 及治疗结束2周后,NRS 评分治疗组高或低于对照组,差异有统计学意义(P <0.05);治疗14,28 d 时,差异无统计学意义(P >0.05)。结论:加味益气丸联合养血止痛丸治疗致密性髂骨炎安全有效,值得推广应用。%[ABSTRACT] Objective:To observe the clinical effect and safety of Jiawei Yiqi Wan(加味℃气丸) combined with Yangxue Zhitong Wan(养血止痛丸) in the treatment of sacroiliac joint sclerosing osteitis.Methods:54 cases of sacroiliac joint sclerosing osteitis were randomly divided into a treatment group and a control group, 27 cases in each.The treatment group was orally given Jiawei Yiqi Wan and Yangxue Zhitong Wan,6 g each time and twice a day;while the control group was orally given celecoxib capsule,200 mg each time and twice a day. The two groups were treated for 4 weeks,observing NRS scores and clinical efficacy before treatment,after 3,7,14 , 28 days,and 2 weeks after treatment,and evaluating their adverse reactions.Results:In the treatment group, 7 cases were cured,13 cases were markedly effective,5 cases were improved,and 2 cases were ineffective,the total effective rate being 92.59%,while in the control group,2 cases were cured,5 cases were markedly effective, 11 cases were improved,and 8 cases were ineffective,the total effective rate being 69.23%.The difference between the two groups was statistically significant (P < 0.05).After treatment,the NRS pain scores of the two groups were significantly lower than those before treatment,and the difference was statistically significant (P < 0.05). After 3 days,7days and 2 weeks of treatment,the NRS scores of the treatment group were significantly lower than those of the control group,and the difference was statistically significant (P < 0.05).After 14 and 28 days of the treatment,the difference between groups was not statistically significant (P > 0.05). Conclusion:Jiawei Yiqi Wan combined with Yangxue Zhitong Wan is safe and effective in the treatment of sclerosing osteitis,worthy of popularization and application.